{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:32:36Z","timestamp":1790865156409,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clim.2021.108723","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T02:02:43Z","timestamp":1617760963000},"page":"108723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products"],"prefix":"10.1016","volume":"227","author":[{"given":"Ariel","family":"Kenig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Ishay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Kharouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limor","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clim.2021.108723_bb0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.clim.2021.108723_bb0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"2","key":"10.1016\/j.clim.2021.108723_bb0020","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/jmv.26408","article-title":"Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis","volume":"93","author":"Sarkar","year":"2021","journal-title":"J. Med. Virol."},{"issue":"27","key":"10.1016\/j.clim.2021.108723_bb0025","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1503\/cmaj.200642","article-title":"Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis","volume":"192","author":"Devasenapathy","year":"2020","journal-title":"Cmaj."},{"key":"10.1016\/j.clim.2021.108723_bb0030","doi-asserted-by":"crossref","unstructured":"Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 3832020. p. 2291\u20133.","DOI":"10.1056\/NEJMc2031364"},{"key":"10.1016\/j.clim.2021.108723_bb0035","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3389\/fonc.2020.01578","article-title":"Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab","volume":"10","author":"Kos","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.clim.2021.108723_bb0040","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clim.2021.108723_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00005-008-0014-5","article-title":"The role of B lymphocytes as antigen-presenting cells","volume":"56","author":"Chen","year":"2008","journal-title":"Arch. Immunol. Ther. Exp."},{"issue":"6","key":"10.1016\/j.clim.2021.108723_bb0050","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2021.108723_bb0055","doi-asserted-by":"crossref","first-page":"102120","DOI":"10.1016\/j.msard.2020.102120","article-title":"COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?","volume":"42","author":"Novi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"20","key":"10.1016\/j.clim.2021.108723_bb0060","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:04:28Z","timestamp":1761494668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661621000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":11,"alternative-id":["S1521661621000607"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2021.108723","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2021.108723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108723"}}